ClinicalTrials.gov
public full text
Public Domain
Denosumab for Treating Periprosthetic Osteolysis.
The main objective is to study the efficacy of denosumab in reducing wear-induced osteolysis around uncemented acetabular implants used in total hip arthroplasty. Patients included in the study will receive the same dose of 60 mg denosumab or placebo (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months. The primary endpoint will be the change in volume of the osteolytic lesion over 3 years measured (measured with 3D-CT in cm³).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty#1152122
- The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty#994001
- Data for "In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation"#280735
- Data for "In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation"#280730
- Effects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar Fusion#1059113
Record · ID 850045
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive